All News

Found 522,457 articles

• KanTime adds innovative, seasoned intelligence to their Executive Team

  10/22/2018

  Christopher Taylor has joined KanTime as Vice President of Sales. "I'm excited to be part of one of the fastest growing post-acute EMR Solutions on the market today," said Taylor.

• Prevent Biometrics® Acquires Assets of X2 Biosystems, Consolidating Leadership in Head Impact Monitoring

  10/22/2018

  Prevent Biometrics, the Cleveland Clinic spinoff that developed the first accurate, real-time system for monitoring head impacts in contact sports, today announced that it has acquired the head impact monitoring assets of Seattle-based X2 Biosystems.

• Marapharm Ventures Inc. announces final approval from the State of Nevada for first facility

  10/22/2018

  Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) ("Marapharm" or the "Company") is very pleased to announce to its shareholders, that further to its news release of October 17, 2018, its first facility has been granted the final approval to commence operations, from the State of Nevada.

• Stericycle Inc. Continues Partnership With National Safety Council to Bring Opioid Crisis Campaign to Houston

  10/22/2018

  Stericycle Inc., a leading provider of essential and highly specialized compliance-based solutions, is continuing its partnership with the National Safety Council (NSC) as the exclusive medication disposal partner for its “Stop Everyday Killers” national education campaign addressing the opioid epidemic.

• VerdeMed, a Latin American cannabis company, is sponsoring the 3rd Annual Cannabis Private Investment Summit in Toronto

  10/22/2018

  VERDEMED HOLDINGS INC. ("VerdeMed" or the "Company") proudly announces its sponsorship of  the 3rd Annual Kahner Global Cannabis Private Investment Summit, on October 23, 2018, at the offices of Bennett Jones in First Canadian Place.

• BerGenBio Announces Interim Biomarker and Phase II Clinical Data with Selective AXL Inhibitor Bemcentinib Presented at ESMO

  10/22/2018

  Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second line NSCLC

• Cigna and Connecticut Sustainable Business Council to Host Sustainable Well-being Forum, Connecting Health and Environment

  10/22/2018

  Cigna, a CTSBC member company, will host this event at its Bloomfield headquarters from 5:30 to 8 p.m. T

• Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial

  10/22/2018

  Updated analysis from ongoing Phase 2 trial of sitravatinib in combination with nivolumab demonstrated significant clinical activity in patients with checkpoint refractory non-small cell lung cancer (NSCLC)

• Axcella Appoints Stephen Mitchener, PharmD, to Senior Vice President, Chief Business Officer

  10/22/2018

  Dr. Mitchener brings 15 years of pharmaceutical industry experience driving domestic and international commercialization, BD&L, operations, and value creation to Axcella.

• New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder

  10/22/2018

  Takeda Pharmaceuticals U.S.A., Inc. ("Takeda") and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for TRINTELLIX® (

• Sensus Healthcare to Host Third Quarter 2018 Financial Results and Business Update Conference Call on November 1, 2018

  10/22/2018

  Management will also provide a business update and a discussion on recent and upcoming milestones.

• Second Sight Completes $4 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors

  10/22/2018

  This placement of common stock is anticipated to yield gross proceeds of approximately $4 million to the Company.

• FDA Grants Breakthrough Device Status for MediBeacon's Transdermal GFR Measurement System

  10/22/2018

  MediBeacon's Breakthrough Device is Intended to Measure GFR in Patients with Impaired or Normal Kidney Function

• Axcella to Present New Data at the Annual 2018 AASLD Liver Meeting

  10/22/2018

  Effective therapies for NAFLD require coordinated reprogramming of cellular physiology as multiple pathways drive liver injury and disease progression.

• Anaeropharma Science Signs Collaborative Research Agreement with Chugai on Creation of Novel Oncology Drugs Using Bifidobacterium

  10/22/2018

  Anaeropharma Science Inc. announced on October 22 that Anaeropharma Science and Chugai Pharmaceutical Co., Ltd. headquartered in Tokyo (hereinafter "Chugai") have concluded a collaborative research agreement concerning the creation of novel oncology drugs utilizing characteristic features of Bifidobacterium longum through Anaeropharma's proprietary platform technology, "in situ Delivery and Production System" (hereinafter "i-DPS").

• Rush University Medical Center Partners with Connexient to Integrate Indoor Navigation with Epic's MyChart Appointment Scheduling in the MyRush Mobile App

  10/22/2018

  Connexient announced today a partnership with Rush University Medical Center in Chicago to integrate the MediNav™ solution with the MyRush Mobile app; a mobile app for patients powered by Epic's MyChart. Rush is the first Connexient customer that will combine Indoor GPS with appointment scheduling in MyChart.

• Evergreen Pacific Insurance Corporation Closes Acquisition of Majority Interest in Synergy Health Services

  10/22/2018

  Evergreen Pacific has added Synergy's network of multi-disciplinary wellness centres, combining traditional medical pain management with allied health services, to the Evergreen Pacific group of companies, aligned with Evergreen Pacific's focus on improved patient outcomes.

• Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures

  10/22/2018

  Senior management of Sinovac Biotech Ltd. and the lawful directors of Sinovac Hong Kong (“Lawful Directors”), Mr. Yin Weidong and Ms. Wang Nan, have been granted interim injunctive relief against Mr. Li Pengfei (“Mr. Li”) and Mr. Cao Jianzeng (“Mr. Cao”) by the High Court of the Hong Kong Special Administrative Region

• Adesis, Inc. Commemorates State-of-the-Art Laboratory Expansion with Ribbon Cutting Ceremony

  10/22/2018

  A ribbon cutting ceremony was held on October 19, 2018 to commemorate this expansion with state and local officials, and other members of the Delaware community.

• Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist

  10/22/2018

  BHV-3500 is the first small molecule calcitonin gene-related peptide (CGRP) receptor antagonist to be administered in an intranasal (IN) formulation in human testing